Lina Concierge Med Spa Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

A medication study and a telehealth company’s treatment page answer different questions. That distinction matters at Lina Concierge Med Spa, which advertises compounded GLP-1 programs alongside peptide and wellness offerings. Its website documents starting prices, an online intake, independent prescribers and home delivery. Those details help explain the service being sold. They do not establish that Lina’s specific preparations produce the results reported in clinical trials, or that its microdose and oral options share the evidence supporting a different formulation or route.

This review examines public documentation consulted October 19, 2026, separating service descriptions from clinical evidence and contractual commitments. Lina provides useful information about included care, prescription decisions and some eligibility restrictions. However, the consulted material does not identify its dispensing pharmacies, fully specify every GLP-1 offering or reconcile conflicting cancellation deadlines. Professional credentials and pharmacy licensing are reported here as website statements, not independent verification. The most useful reading is therefore neither an endorsement nor a dismissal, but an examination of what a prospective patient can actually confirm.

At a glance

Service structure: Lina describes itself as a telehealth platform connecting patients with independent clinicians and compounding pharmacies; it says the platform itself does not prescribe or dispense.
Sources: [8]
Advertised GLP-1 starting prices: The catalog lists semaglutide injection from $139/month, tirzepatide injection from $166/month, GLP-1 Microdose from $199/month and GLP-1 Oral from $229/month.
Sources: [11]
Compounded-product status: Lina acknowledges that compounded medications are not FDA approved. FDA recommends them when an individual’s medical needs cannot be met by an approved drug.
Sources: [8] [1]
Recurring billing: The terms authorize an immediate charge and subsequent charges every 30 days for recurring monthly orders, with electronic notice five to seven days before a scheduled transaction.
Sources: [7]
Unresolved cancellation conflict: Treatment pages require 30 days’ notice before the next billing cycle, while the terms describe cancellation through the portal at least 48 hours before monthly processing.
Sources: [12] [7]

Start with the business behind the treatment claims

Lina attributes its founding to Melissa Linares, NP, whom the homepage describes as a board-certified nurse practitioner in acute care. That is a nursing credential, not a physician credential. The brand presents a concierge approach to weight management and peptide therapy, while its disclaimer assigns consultations, clinical evaluations and prescription decisions to independent licensed practitioners. This separation matters: the commercial platform, treating clinician and dispensing pharmacy have different responsibilities, even when the patient encounters them through one website.

The business advertises fully remote care across all 50 states, without a physical office for patient visits. Its terms qualify that broad claim: availability depends on state-specific rules and may change. They also require patients to be physically located in the same state as the shipping address during consultation. Nationwide advertising therefore should not be read as confirmation that every listed treatment is available to every person in every jurisdiction.

The terms introduce another identity question. An opening arbitration notice names Lina Concierge Med Spa, LLC, while other clauses name Melissa Caramanica Nurse Practitioner in Acute Care PLLC. The consulted passages do not explain their relationship. That inconsistency does not establish wrongdoing, but it leaves the contracting structure unclear. Before paying, a reader can reasonably request the legal names of the platform, medical group and pharmacy, along with which organization handles clinical complaints, billing disputes and records requests.

Sources: [9] [8] [12] [7]

The catalog identifies programs, but not every preparation

Lina’s catalog separates injectable semaglutide and tirzepatide from two less fully specified offerings: GLP-1 Microdose and GLP-1 Oral. The semaglutide treatment page describes a weekly compounded injection, and Lina also advertises compounded tirzepatide. By contrast, the consulted microdose material does not establish its active ingredient, formulation or route. The oral catalog entry describes a daily option without identifying its active ingredient. Those are material distinctions, not simply missing marketing details.

The microdose page targets people near their goal weight, those who previously tolerated standard GLP-1 dosing poorly and people incorporating the program into broader wellness plans. It also excludes patients with substantial weight to lose who, in the clinician’s judgment, would be better served by a standard program. These are Lina’s advertised positioning and screening statements. They are not clinical evidence that the unspecified preparation delivers the claimed metabolic, body-composition or appetite benefits.

The broader catalog includes tesamorelin from $299/month, sermorelin from $249/month, NAD+ from $146/month and PT-141 from $249/month. Lina explicitly describes NAD+ as a coenzyme rather than a peptide. Listing these products establishes the breadth of the business, not their effectiveness for a particular purpose. For each proposed treatment, the useful next question is the exact prescription: ingredient, formulation, route, dispensing pharmacy and intended clinical objective.

Advertised GLP-1 programs: starting prices and documentation boundaries
Program	Advertised starting price	What remains unresolved
Semaglutide injection	From $139/month	Supply quantity and complete starting-price conditions
Tirzepatide injection	From $166/month	Supply quantity and complete starting-price conditions
GLP-1 Microdose	From $199/month	Active ingredient, formulation and route
GLP-1 Oral	From $229/month	Active ingredient and complete formulation

Sources: [12] [11] [6]

Clinical research is not a performance report for Lina

Lina acknowledges that compounded medications are not FDA approved and that FDA has not independently verified their safety, efficacy and quality. FDA approval attaches to a specific product, not to a clinic or pharmacy. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence, but neither does a familiar ingredient name establish that a compounded preparation has the same evidence as an approved product.

The research context includes STEP 1, which studied subcutaneous semaglutide against placebo for 68 weeks in adults with obesity or overweight plus a weight-related condition, without diabetes. Both groups received lifestyle intervention; gastrointestinal events caused more discontinuations with semaglutide, and Novo Nordisk funded the trial. SURMOUNT-1 studied subcutaneous tirzepatide against placebo for 72 weeks in adults with obesity or overweight plus a complication, excluding diabetes. Gastrointestinal adverse events were common, and Eli Lilly funded that trial.

Neither trial evaluated Lina’s service, its compounded prescriptions, its oral offering or its microdose program. Their findings cannot establish outcomes for those products or predict an individual’s response, and comparing the trials is not a randomized head-to-head comparison. Our explanation of why a clinical trial is not a provider performance report develops this boundary. The related distinction between approved medicines and compounded preparations helps explain why pharmacy licensing and product-specific evidence answer different questions.

Sources: [8] [1] [3] [4]

Intake is documented more clearly than clinical timing

The homepage describes an online assessment collecting health history, weight goals and baseline measurements. Its estimated five to ten minutes refers to completing that form, not clinician review or prescription approval. The terms require a consultation, a clinician’s determination that the product is appropriate and issuance of a prescription before a prescription product can be obtained. Although marketing says no appointments or clinic visits are needed, that should not be mistaken for treatment without clinical evaluation.

General access requires adulthood: at least 18, or the jurisdiction’s age of majority if higher. Lina’s semaglutide and tirzepatide pages describe candidates as adults with BMI of at least 27, or at least 25 with weight-related conditions. The tirzepatide page also discusses patients who have plateaued on a single-agonist GLP-1. These are the provider’s published criteria, not individualized eligibility advice. NIDDK’s general adult pharmacotherapy thresholds differ, underscoring why an advertised cutoff is not a complete clinical assessment.

The semaglutide page lists exclusions including personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or planned pregnancy; active pancreatitis; and untreated severe gastrointestinal disease. The documentation does not establish laboratory requirements, testing costs or a clinical-review deadline. A practical pre-enrollment request is therefore a written explanation of required records and tests, who reviews them, and whether any charges arise before the clinician determines that a program is appropriate.

Sources: [8] [7] [12] [13] [2]

Follow the prescription through pharmacy, delivery and follow-up

The semaglutide program describes included compounded medication, a dedicated provider, direct portal messaging and recurring check-ins. The homepage says follow-ups are scheduled as needed, but the consulted documents do not specify a minimum visit frequency or response standard for clinical messages. These descriptions suggest ongoing access rather than a prescription-only transaction. They do not establish how often an individual will be assessed, which measurements will be reviewed or who provides coverage when the usual clinician is unavailable.

Lina says U.S.-licensed compounding pharmacies prepare its protocols, but the relevant passages do not name them. Its terms also restrict pharmacy choice: purchasing a prescription-containing service means accepting fulfillment through pharmacies accessible through the platform rather than an outside pharmacy of the patient’s choosing. Another consequential provision states that prescription products will not be dispensed in child-resistant containers. Readers should obtain pharmacy identification and understand the packaging arrangements before medication processing begins.

Delivery is described as temperature-controlled, discreet and unmarked, with medication shipped on a structured cadence. No specific preparation, dispatch or arrival timetable is established, and the consulted material does not resolve shipping charges or temperature-incident procedures. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated, and contacting the provider or dispensing pharmacy. Our guide to reading cold-chain delivery claims explains why a packaging promise is not confirmation of an individual shipment’s condition.

Sources: [8] [12] [7] [1]

Starting prices do not settle the full payment arrangement

The homepage advertises plans from $139/month, with the price confirmed after provider review. Treatment pages describe flat-rate programs with no hidden fees, unexpected consultation charges or dose-change surcharges. The terms explain that prescription-containing subscriptions bundle pharmacy charges, medical-group services and platform access. These are meaningful representations about included services. Nevertheless, the catalog’s starting amounts are not guaranteed prices for every patient, and the consulted summaries do not specify supplied quantities, minimum commitments or complete conditions for obtaining those rates.

For recurring monthly orders, the terms authorize charging immediately and every 30 days thereafter until cancellation. That is a specific billing interval, not necessarily the same date each calendar month. Electronic notification is promised five to seven days before a scheduled transaction, followed by a receipt after successful payment. The documentation does not establish an introductory-versus-renewal price schedule or a separate prepaid alternative, so neither should be assumed from the monthly catalog figures.

The homepage also says insurance is not required. That does not answer whether Lina accepts insurance, submits claims, supports out-of-network reimbursement or accepts HSA/FSA payments. Nor do the consulted documents settle laboratory charges or shipping fees. A written quote should identify the exact program, first charge, recurring amount, medication quantity and any separate expenses. This is particularly important when a bundled program’s appealing headline price is easier to find than the operational details governing payment.

Sources: [8] [12] [7]

Cancellation and refunds need written reconciliation

The clearest contractual problem is a direct cancellation conflict. Treatment pages require 30 days’ notice before the next billing cycle. The terms instead permit cancellation by disabling auto-refill in the portal at least 48 hours before the monthly processing date. These are materially different deadlines. A reader should not assume the shorter deadline overrides the longer one, or that a renewal reminder arriving five to seven days before billing would satisfy the treatment page’s notice requirement.

Refund language adds a separate boundary. The treatment page says consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. Meanwhile, the homepage says a person is never charged if a program is not the right fit. Those statements might apply at different stages, but the consulted passages do not explain the transition. Cancellation of future renewals also does not establish entitlement to reimbursement for a payment already taken.

Before enrollment, useful written questions include which cancellation rule governs the specific purchase, which date counts as processing, how cancellation is acknowledged, and what happens if the clinician declines treatment after an initial charge. Save the response alongside the purchase terms and quoted price. The available terms also contained an omitted middle section, so this review cannot characterize the entire agreement. It can identify the conflicts present in the passages available for consultation.

Sources: [12] [7] [8]

Privacy promises and contact access require separate scrutiny

Lina markets its intake as secure and HIPAA compliant, including encrypted storage. Its terms state that Lina itself is not a HIPAA covered entity and may act as a business associate of a pharmacy or medical group in certain circumstances. These statements are not necessarily incompatible, because organizational roles differ. But a broad privacy assurance does not explain which entity holds each category of information or which protections apply throughout the platform, clinical and advertising systems.

There is also tension between a treatment FAQ’s general assurance that data are never sold or shared and the California notice’s description of disclosures for advertising. That notice says some disclosures may count as a sale or sharing under California law. This is a reason to request a clear explanation of advertising-data practices, applicable choices and information flows—not a basis for inventing a legal conclusion. Public statements alone do not independently verify the platform’s privacy implementation.

For practical access, Lina publishes info@linaconciergemedspa.com, a patient-portal sign-in and support hours Monday through Saturday, 9 a.m. to 6 p.m. Eastern. The contact form promises a team response within 24 hours; that is not a clinical-review, prescribing or delivery deadline. Spanish-language care and interpreter availability are not confirmed. Readers evaluating these promises can use our guide to what public provider documents can prove to distinguish an accessible contact channel from a verified service-performance record.

Sources: [8] [7] [5] [10] [12]

Questions & answers

Does Lina offer FDA-approved GLP-1 medication?

The reviewed offering emphasizes compounded GLP-1 programs, and Lina expressly acknowledges that compounded medications are not FDA approved. The consulted material does not establish an approved-brand dispensing option. FDA recommends compounded drugs when an individual’s needs cannot be met by an approved drug. Ask which exact product would be prescribed rather than treating the ingredient name as confirmation of approval.

Sources: [8] [1]

Is semaglutide guaranteed to cost $139 each month?

No. The catalog says semaglutide injection starts at $139/month, and the homepage says pricing is confirmed after provider review. Treatment pages advertise flat-rate pricing without dose-change surcharges, but the consulted material does not establish every starting-price condition or supply quantity. Request the actual recurring quote and what it includes before authorizing a subscription.

Sources: [11] [8] [12]

Can I take a Lina prescription to my preferred pharmacy?

The terms say that purchasing a service containing a prescription requires accepting fulfillment through the platform’s pharmacy channel and waiving outside pharmacy choice. The consulted treatment passage describes licensed U.S. compounding pharmacies without naming them. Anyone for whom pharmacy choice is important should resolve that restriction before purchasing, rather than assuming a prescription can later be transferred.

Sources: [7] [12]

How quickly will Lina review my intake and deliver medication?

The documented five-to-ten-minute estimate concerns completing intake. The contact form’s 24-hour promise concerns a team response. Neither establishes a clinical-review deadline, pharmacy preparation time, dispatch date or arrival date. Lina describes temperature-controlled home delivery, but the consulted material does not provide a complete fulfillment timeline. Ask for each stage separately, including what happens if shipment is delayed.

Sources: [8] [10] [12]

How do I cancel, and will I receive a refund?

The documents conflict: treatment pages require 30 days’ notice, while the terms describe disabling portal auto-refill at least 48 hours before monthly processing. Obtain written clarification of the applicable rule. Refunds are a separate issue: the treatment page excludes refunds once services begin or medication is processed. Canceling future payments does not itself reverse an earlier charge.

Sources: [12] [7]

Does Lina provide ongoing access to a clinician?

The semaglutide program advertises a dedicated provider, direct messaging through a secure portal and periodic check-ins; the homepage describes follow-ups as needed. The consulted material does not establish a minimum follow-up schedule or clinical-message response time. Ask who handles new symptoms, who covers absences and whether additional appointments or testing can create charges outside the quoted program.

Sources: [12] [8]

Our assessment

Lina documents a recognizable telehealth model: independent prescribing, compounded medication, portal access and home delivery, with visible starting prices and stated flat-rate inclusions. Its acknowledgment of compounded-product limitations is useful. However, the public record is less complete on exact microdose and oral preparations, pharmacy identity, clinical timing and testing costs. Conflicting cancellation deadlines, unexplained contractual names and differing privacy statements deserve written clarification before payment. Clinical trials provide background evidence, not validation of Lina’s particular products or outcomes. The practical decision point is whether the company can supply a clear, patient-specific prescription description, accountable care team and consistent financial terms—not whether its marketing uses familiar medication names.

Visit Lina Concierge Med Spa’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Lina Concierge Med Spa Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Start with the business behind the treatment claims

02The catalog identifies programs, but not every preparation

03Clinical research is not a performance report for Lina

04Intake is documented more clearly than clinical timing

05Follow the prescription through pharmacy, delivery and follow-up

06Starting prices do not settle the full payment arrangement

07Cancellation and refunds need written reconciliation

08Privacy promises and contact access require separate scrutiny